Senseonics (NYSEAMERICAN:SENS) Shares Gap Up to $1.29

Senseonics Holdings, Inc. (NYSEAMERICAN:SENSGet Rating)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $1.29, but opened at $1.32. Senseonics shares last traded at $1.37, with a volume of 18,088 shares trading hands.

Senseonics Price Performance

The company has a market cap of $634.67 million, a PE ratio of -1.65 and a beta of 0.61.

Senseonics (NYSEAMERICAN:SENSGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $2.48 million for the quarter, compared to the consensus estimate of $2.14 million. On average, equities analysts expect that Senseonics Holdings, Inc. will post -0.16 EPS for the current year.

Hedge Funds Weigh In On Senseonics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SENS. Vanguard Group Inc. boosted its holdings in shares of Senseonics by 6.5% in the 1st quarter. Vanguard Group Inc. now owns 21,431,413 shares of the company’s stock worth $42,221,000 after purchasing an additional 1,306,932 shares in the last quarter. State Street Corp boosted its holdings in shares of Senseonics by 10.5% in the 1st quarter. State Street Corp now owns 12,630,322 shares of the company’s stock worth $24,882,000 after purchasing an additional 1,205,001 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of Senseonics in the 4th quarter worth about $1,537,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Senseonics by 682.4% in the 4th quarter. BNP Paribas Arbitrage SA now owns 605,807 shares of the company’s stock worth $1,618,000 after purchasing an additional 528,380 shares in the last quarter. Finally, Laidlaw Wealth Management LLC purchased a new stake in Senseonics during the 1st quarter valued at about $756,000. 26.81% of the stock is currently owned by hedge funds and other institutional investors.

About Senseonics

(Get Rating)

Senseonics Holdings, Inc, a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months.

Featured Articles

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.